Dec 26
|
Merck (MRK) & Daiichi Sankyo's Lung Cancer ADC Gets Priority Tag
|
Dec 24
|
2 Small Cap Stocks That Could Go Parabolic in 2024, According to Wall Street
|
Dec 21
|
GSK, Hansoh Ink Deal to Develop Lung Cancer ADC Candidate
|
Dec 20
|
Botensilimab/Balstilimab Data in Neoadjuvant Colorectal Cancer Selected for ASCO-GI 2024
|
Dec 13
|
Blueprint (BPMC) Gets EC Nod for Ayvakit Expanded Use, Stock Up
|
Dec 11
|
Agenus to Receive $25 Million Milestone Payment from Bristol Myers Squibb for TIGIT-CD96 Bispecific Program
|
Dec 7
|
Century (IPSC) Up 36% on FDA Nod to Begin Phase I Lupus Study
|
Dec 7
|
Dr. Reddy's (RDY), COYA Ink Deal to Develop COYA 302 for ALS
|
Dec 6
|
Agenus (NASDAQ:AGEN) adds US$36m to market cap in the past 7 days, though investors from three years ago are still down 75%
|
Nov 30
|
Acadia (ACAD) Begins Alzheimer's Disease Psychosis Study (Revised)
|
Nov 9
|
Rainbows and Unicorns: Agenus Inc. (NASDAQ:AGEN) Analysts Just Became A Lot More Optimistic
|
Nov 7
|
Agenus Inc (AGEN) Reports Q3 2023 Results: Revenue of $24.3 Million and Net Loss of $64.5 Million
|
Nov 7
|
Agenus Reports Third Quarter 2023 Results
|
Aug 24
|
Agenus (AGEN) to Focus on BOT/BAL Candidate, Stock Falls 7%
|
Aug 23
|
Watertown biotech shares spike after accidental data publication at Roche
|
Aug 23
|
Lexington biotech lays off 91 as it narrows focus
|
Aug 23
|
Agenus Prioritizes Resources to Accelerate Registration and Commercialization of BOT/BAL Program in Multiple Cancers
|
Apr 26
|
Agenus to Present at the American Society of Clinical Oncology 2023 Annual Meeting
|
Apr 25
|
Agenus to Provide Corporate Update and First Quarter 2023 Financial Report
|
Apr 24
|
Agenus to Participate in May Investor Conferences
|